Navigation Links
Bedford Laboratories(TM) Announces the Acquisition of CAFCIT(R) (Caffeine Citrate) Injection CAFCIT(R) (Caffeine Citrate) Oral Solution
Date:1/3/2008

BEDFORD, Ohio, Jan. 3 /PRNewswire/ -- Bedford Laboratories(TM), a division of Ben Venue Laboratories Inc., announced the acquisition of CAFCIT(R) (caffeine citrate) Injection and CAFCIT(R) (caffeine citrate) Oral Solution from Mead Johnson & Company. Bedford Laboratories is now the reference listed drug holder. CAFCIT(R) (caffeine citrate) is indicated for the short term treatment of apnea in premature infants between 28 and <33 weeks gestational age.

(Logo: http://www.newscom.com/cgi-bin/prnh/20070809/CLTH157LOGO )

"The acquisition of CAFCIT(R) demonstrates our continued commitment to build the most comprehensive and cost effective line of injectable products in the pharmaceutical industry. We are proud to offer a branded product at a generic price," said David Gaugh, Vice President and General Manager of Bedford Laboratories.

Bedford Laboratories will supply latex free CAFCIT(R) (caffeine citrate) Injection and CAFCIT(R) (caffeine citrate) Oral Solution as a sterile liquid in the following presentations:

-- Injection: 60 mg/3 mL single-use vials individually boxed

-- Oral Solution: 60 mg/3 mL single-use vials, 10 vials per child-

resistant container

Prescribing information is available upon request from the Bedford Laboratories' professional services department, (800) 521-5169, or from the company's web site, http://www.bedfordlabs.com.

About Bedford Laboratories

Bedford Laboratories supplies the US and international markets with multisource and specialty injectable products. Headquartered in Bedford, Ohio, Bedford Laboratories is a division of Ben Venue Laboratories, Inc., a subsidiary of Boehringer Ingelheim Corporation located in Ridgefield, CT, and is a part of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim <
'/>"/>

SOURCE Bedford Laboratories
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Alma Lasers Announces Proposed Initial Public Offering
2. Smart Balance Announces Conversion of Convertible Preferred Stock
3. IDM Pharma Announces Termination of UVIDEM Development Collaboration and Expected Restructuring in Connection With Evaluation of Strategic Alternatives
4. MQ Associates, Inc. Announces Cash Tender Offer for 121/4% Senior Discount Notes Due 2012 (CUSIP No. 55345RAC2) and Related Consent Solicitation
5. Heska Announces Amended Agreement With AgriLabs
6. Versus Technology Announces Fourth Quarter Results
7. FASgen Announces New Research Discoveries in Lung Cancer
8. Boston Scientific Announces CE Mark Approval for Next-Generation Cardiac Resynchronization Therapy Defibrillator
9. KV Pharmaceutical Company Announces NYSE Listing Extension
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic OTC Versions of Zyrtec Allergy Tablets(R) and Zyrtec Hives Relief Tablets(R)
11. Transition Therapeutics Announces Appointment of Vice-President of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/4/2009)...nt pain and injury, doctors say , , SATU...s are not as young as they used to be, exercise is...s are in order to stay injury-free. , "As bo... themselves from injuries when exercising," Dr. Ra...rthopaedic Surgeons, said in a news release. "A li...
(Date:7/3/2009)...gnise service excellence during National Customer ... London (PRWeb UK) July 3, 2009 -- Companies ...d to celebrate the importance of excellent custome...ice Week - 5-11 October., , ,Employers in all sect...and local authority see the week, which is organis...
(Date:7/3/2009)... in middle age may triple the risk, study shows ,...iddle-aged adults who live alone are twice as like...r in life compared to those who are married or liv...er among those who are divorced or widowed, accord...ers. , The study included 2,000 men and women i...
(Date:7/3/2009).../ -- Sundia MediTech, a leading,integrated pharma...n Shanghai,China announced today that Dr. Chen C...hemistry Services. , Prior to joining Sundi...ug,discovery and development company in San Diego...ior Director of Medicinal Chemistry of Neurocrine....
Breaking Medicine News(10 mins):Health News:Exercise Tips to Keep Boomers on Their Feet 2Health News:Businesses Urged to Sign Up and Celebrate Customer Service 2Health News:Living Alone Increases Odds of Developing Dementia 2Health News:Sundia MediTech Appoints Dr. Chen Chen as Senior VP of Chemistry 2
...s at loggerheads with the pharmaceutical industry ... generic medicines. // While Thailand argues it wi...to its citizens, drug companies maintain that the ...and discourages foreign investment. "We were disa...
...e awareness about the ill effects of obesity in ch.../ The game is named as "Body Mechanics," and teach...laying the game. The game begins with an introduc...uro, a Yoda-like wise man. He requests players to ...
...approved by the UAE Ministry of Health (MOH) again...warded with a //prequalification status by the Wor... a vaccine against rotavirus gastroenteritis has r...fication endorses the Rotarix quality, safety and ...
...egulator said it has adopted a positive opinion re...on for Focetria, from Novartis //AG (NVS) Vaccines...demic influenza vaccine, intended for the preventi...eclared pandemic situation, once the pandemic vira...
Other Medicine News:Health News:Drug Companies Hit Out at Thai Generic Drug Scheme 2Health News:WHO Awards Prequalification Status to the First UAE Approved Vaccine 2
(Date:7/3/2009)... -- BioCis Pharma Ltd., a privately,held drug dev...inland,announced positive results from its Phase...am, the company,s novel topical drug for dermatolo...conducted in Finland, included 13,patients with m...ProtoCure,emulsion cream to the affected skin are...
(Date:7/2/2009)... Eisai Co., Ltd. (Headquarters: Tok... Eisai Corporation of North America (Headquarters:...zu) are currently focusing on three clinical devel...icept(R) (donepezil hydrochloride tablets) to furt...e. As progress in those programs has been made, Ei...
(Date:6/30/2009)...-- If you have been eating Garlic to keep the mosq...ere is absolutely no scientific evidence that eati... garlic has plenty of evidence to prove it keeps t...y lawns is not as strange as it seems. Mosquito Ba...s being used successfully by city parks, golf cour...
(Date:6/30/2009)...all/ -- Cephalon, Inc. (Nasdaq: CEPH ) today ann...ug Application (sNDA) to the U.S. Food and Drug Ad...R) (armodafinil) Tablets [C-IV] for the indication...e sleepiness associated with jet lag disorder resu...an acute condition that occurs when a person,s int...
Breaking Medicine Technology:BioCis Pharma Reports Positive Phase IIa Clinical Results in Atopic Dermatitis 2Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value 2Current Status of the Development Programs of New Indications and Formulations for Aricept(R) for Enhancing Patient Value 3Keep Mosquitoes and More Out of Your Yard with Garlic From Garlic Research Labs, Inc. 2Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder 2Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder 3Cephalon Submits NUVIGIL Supplemental New Drug Application for the Treatment of Excessive Sleepiness Associated with Jet Lag Disorder 4SENOMYX ANNOUNCES THE EXTENSION OF ITS COLLABORATIVE RESEARCH DEVELOPMENT COMMERCIALIZATION AND LICENSE AGREEMENT WITH AJINOMOTO CO INC 11181 1SENOMYX ANNOUNCES THE EXTENSION OF ITS COLLABORATIVE RESEARCH DEVELOPMENT COMMERCIALIZATION AND LICENSE AGREEMENT WITH AJINOMOTO CO INC 11181 2SENOMYX ANNOUNCES THE EXTENSION OF ITS COLLABORATIVE RESEARCH DEVELOPMENT COMMERCIALIZATION AND LICENSE AGREEMENT WITH AJINOMOTO CO INC 11181 3How Long Will the Economic Downturn Affect the Dental Biomaterials Market 3F 11179 1How Long Will the Economic Downturn Affect the Dental Biomaterials Market 3F 11179 2Anesthesia in Youngest Kids May be Linked to Learning Disabilities 40452 1Anesthesia in Youngest Kids May be Linked to Learning Disabilities 40452 2Anesthesia in Youngest Kids May be Linked to Learning Disabilities 40452 3Just Say No To Charcoal 21 New Eco Friendly Alternative Grills Faster Burns Cleaner And Greener 11178 1Just Say No To Charcoal 21 New Eco Friendly Alternative Grills Faster Burns Cleaner And Greener 11178 2
...ass.--(BUSINESS WIRE)--Jul 6, 2007 - BusinessWeek ...pharmaceutical and,biotechnology companies to be f...treatment for cardiovascular disease. While,angiog...is, Boston,Scientific, Baxter, and Genzyme, among ...w biological therapy for advanced,coronary artery ...
..., N.J., July 05, 2007 /PRNewswire/ -- Results from... open-label, Phase,3 study showed that 77 percent ...ing PREZISTA(TM) (darunavir) 600 mg tablets with,1...optimized,background regimen (OBR) of antiretrovir...00 copies/mL at week 48, compared to 68,percent of...
Other Medicine Technology:BusinessWeek Article Highlights Promising Breakthrough Treatment,for Advanced Coronary Artery Disease 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 2New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 3New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 4New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 5New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 6New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 7New Phase 3 Study Published in The Lancet Evaluates Efficacy and,Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination,Therapy in Treatment-Experienced Adults With HIV 8
Lab-Reader
Fully automatic NRTL and CE certified microplate reader.
Chameleon is a compact and versatile multilabel microplate reader. The patented optical design allows up to six measurement technologies including liquid scintillation counting, luminescence, absorba
Elisa strip reader for single strips or break-away format. On board software calculates single & multi-point calibration curves, regressions, & a variety of cutoff.
Medicine Products: